Mechanisms and rationale for menin inhibitor combination strategies in AML
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Mechanisms and rationale for menin inhibitor combination strategies in AML
-
ナレーター：
-
著者：
The AML Hub was pleased to speak with Eunice Wang from Roswell Park Comprehensive Cancer Center, Buffalo, US. We asked, What are the mechanisms and rationale for menin inhibitor combination strategies?
Wang summarizes the rationale for menin inhibitor combination strategies for the treatment of NPM1-mutated (NPM1m) or KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML), including their potential for improving outcomes and reducing the risk of on-target and off-target resistance vs menin inhibitor monotherapy. Wang also suggests mechanisms by which combination strategies might mitigate the risk of differentiation syndrome.
Intended for healthcare professionals only. This educational resource is independently supported by Kura Oncology. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.
Hosted on Acast. See acast.com/privacy for more information.